Biopharmaceuticals

Experienced, qualified staff and investment in the latest technologies allow us to provide high quality bioanalytical services for biopharmaceuticals in support of all stages of your development.

Quotient’s unique heritage in sports drug surveillance and biomarker discovery has created an innovative bioanalytical group with a broad range of capabilities and expertise for the analysis of pharmaceuticals.

Working in close partnership with our clients, we maintain an up-to-date understanding of the dynamic regulatory environment in important areas such as macromolecule validation and immunogenicity testing. 

We are also pioneers in the evaluation and adoption of new analytical technologies and approaches.  For example, Quotient was the first to publish the use of UPLC-MS for the quantification of proteins in biological fluids which led to the development of our BioMS™ service.  We were also the first GLP laboratory to acquire a Gyrolab platform, now a key component in our analytical tool box for biopharmaceuticals, biomarkers and immunogenicity.

Our bioanalytical services for biopharmaceuticals include:

• New method development
• Method validation (GLP, GCP or non-regulated)
• Sample analysis to support discovery, preclinical and clinical programmes
• Macromolecule quantification and characterisation to support biopharmaceutical development and manufacture.

UPLC-MS - Ultra high pressure liquid chromatography - mass spectrometry; BioMS™ - Biologicals measured by mass spectrometry; GLP - Good Laboratory Practice; GCP - Good Laboratory Practice